Zoetis Inc. $ZTS is Banque Pictet & Cie SA’s 10th Largest Position

Banque Pictet & Cie SA cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,378,772 shares of the company’s stock after selling 152,680 shares during the period. Zoetis accounts for 1.8% of Banque Pictet & Cie SA’s portfolio, making the stock its 10th biggest position. Banque Pictet & Cie SA owned approximately 0.54% of Zoetis worth $299,297,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC increased its position in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis during the 4th quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis during the 3rd quarter valued at about $31,000. Lodestone Wealth Management LLC bought a new position in Zoetis in the fourth quarter worth about $30,000. Finally, Holos Integrated Wealth LLC bought a new position in Zoetis in the fourth quarter worth about $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on ZTS shares. HSBC set a $140.00 price objective on Zoetis in a research report on Wednesday, December 10th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Bank of America lifted their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Barclays initiated coverage on Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target on the stock. Finally, UBS Group set a $136.00 price objective on Zoetis in a report on Thursday, January 29th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Price Performance

Shares of ZTS opened at $117.45 on Thursday. The stock has a market cap of $49.58 billion, a PE ratio of 19.51, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23. The firm’s 50-day simple moving average is $122.97 and its two-hundred day simple moving average is $128.49.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same period last year, the business earned $1.40 earnings per share. The business’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s payout ratio is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.